AXOlabs is an integrated CRO/CDMO specializing in nucleic acid therapeutics (oligonucleotides). Their platform spans from discovery (lead identification and chemistry optimization using bioinformatics-driven design and high-throughput screening) through preclinical safety/PK studies and GLP-compliant bioanalysis to GMP-compliant manufacturing of ASOs, siRNAs, sgRNAs, aptamers, and bioconjugates for clinical phases I-III and initial commercial supply. AXOlabs operates dual-site, globally integrated facilities in Petaluma, California (USA) and Berlin/Kulmbach (Germany), equipped with Cytiva OligoPilot, OligoProcess, and Asahi Kasei THESYS platforms. The company partners with Codexis on enzymatic RNA manufacturing and with Asahi Kasei on oligonucleotide production technologies.
oligonucleotide synthesis and manufacturing, siRNA/ASO development, GMP nucleic acid therapeutics, bioanalytical PNA assay, RNA-Seq off-target analysis, nucleic acid conjugate chemistry
2 sites worldwide
No reviews available yet.
No documents available.